Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-PD1 liquid biopsy biomarker study in NSCLC
jRCT1032220559Not yet recruiting
- Sponsor
- National Cancer Center Hospital
- Start
- Jan 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by National Cancer Center Hospital. Primary endpoint: ctDNA-based MRD evaluation as biomarker of long-term PD-1 inhibitor effectiveness. Planned start Jan 2023; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1032220559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1032220559.